Covina, Sept. 18, 2023 (GLOBE NEWSWIRE) — Scleroderma, also known as systemic sclerosis, is a rare and chronic autoimmune disease that primarily affects the connective tissues in the body. There are various therapeutic approaches aimed at alleviating symptoms, slowing disease progression, and improving the overall quality of life for individuals living with this condition.
Improved awareness of scleroderma among healthcare professionals and the general public can lead to earlier diagnosis and treatment. As a result, more individuals with the condition may seek therapeutic interventions, which further leads to the demand for Scleroderma Therapeutics Market growth.
Key Highlights –
- In August 2023, Scleroderma Research Foundation Launches CONQUEST Platform where Sanofi is the first contributor to this clinical trial platform. This launch is to address critical issues in clinical development and enable advances in systemic sclerosis (SSc) research. The platform will benefit patients, doctors, and drug inventors in numerous ways, including facilitating the transfer to phase 3 international trials, assisting with the analysis of drug activity across a range of genetic backgrounds, and facilitating quick participant recruitment. Also, there are more than 130 centres represented from more than 22 nations.
Analyst View –
The development of more efficient treatments may result from ongoing investigation into the pathophysiology of scleroderma and prospective therapeutic targets. Potentially effective approaches include biologic medicines, tailored treatments, and medications that treat specific diseases. Further, the development of precision medicine makes it possible to customize treatment regimens for particular individuals in light of their genetic and molecular profiles. This results in medicines that are more efficient and well-tolerated.
Scleroderma Therapeutics Market key trends:
- Advancements in Targeted Therapies: Research and development efforts are focused on developing targeted therapies that address the underlying mechanisms of scleroderma. This includes drugs that modulate the immune response and fibrosis pathways, offering the potential for more effective treatments.
- Personalized Medicine: There is a growing emphasis on personalized treatment approaches for scleroderma. Genetic profiling and biomarker identification are helping healthcare providers tailor therapies to individual patients, potentially improving treatment outcomes.
- Combination Therapies: Combination therapies, involving the use of multiple drugs with complementary mechanisms of action, are being explored to enhance treatment efficacy and manage the complex nature of scleroderma.
- Biologics and Monoclonal Antibodies: Biologics and monoclonal antibodies are being investigated as potential treatments for scleroderma. These therapies can target specific immune pathways and are considered promising for reducing inflammation and fibrosis.
- Patient-Centric Care: A patient-centric approach is gaining prominence in scleroderma management. Healthcare providers are focusing on addressing the unique needs and symptoms of patients to improve their quality of life.
“Get your hands on a free sample copy pdf by clicking now”
Scope of the Report:
|The base year for estimation||2020|
|Forecast period||2020 – 2029|
|Market representation||Revenue in USD Million & CAGR from 2020 – 2029|
|Market Segmentation||By Drug Class – Immunosuppressors, Phosphodiesterase 5 Inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, and Others
By Indication – Systemic and Localized
|Regional scope||North America – U.S., Canada
Europe – UK, Germany, Spain, France, Italy, Russia, Rest of Europe
Asia Pacific – Japan, India, China, South Korea, Australia, Rest of Asia-Pacific
Latin America – Brazil, Mexico, Argentina, Rest of Latin America
Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
|Report coverage||Revenue forecast, company share, competitive landscape, growth factors, and trends|
“Get your hands on a free sample copy by clicking now”
Scleroderma Therapeutics Market growth:
- Clinical Trials: Ongoing clinical trials are exploring novel treatments and expanding the therapeutic options available for scleroderma patients. The positive outcomes of these trials can lead to the approval of new therapies, further boosting the market.
- Early Diagnosis: Improved diagnostic techniques and increased awareness among healthcare professionals have led to earlier diagnosis of scleroderma. Early intervention can slow disease progression and enhance treatment outcomes.
- Patient Awareness: Growing patient awareness about the availability of treatments and support for scleroderma is encouraging more individuals to seek medical care, potentially driving market growth.
- Digital Health Solutions: The adoption of digital health technologies, such as telemedicine and remote monitoring, is improving access to healthcare for scleroderma patients, particularly those in remote areas.
- Supportive Care: Advances in supportive care measures, including physical therapy, occupational therapy, and pain management, contribute to better quality of life for scleroderma patients.
Other related Reports:
- Exosomes Market: Size, Trends, Analysis and Forecast till 2032
- Pegfilgrastim Biosimilar Market: Increasing adoption of new technologies and smart solutions with the help of artificial intelligence is the next revolution in patient care that is driving the growth of the market.
- Cleanroom Technology Market: By Product (HVAC, HEPA Filters, Apparel, Vacuum Systems, Gloves, Disinfectants), By Construction (Drywall, Hardwall, Softwall), By End User (Pharmaceutical, Biotechnology, Hospitals) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis, and Forecast till 2030
Follow us on:
LinkedIn | Twitter | Facebook |YouTube
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.